This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coleman, S. Articles by Tabi, Z. Search for Related Content PubMed PubMed Citation Articles by Coleman, S. Articles by Tabi, Z.

Recovery of CD8⁺ T-Cell Function During Systemic Chemotherapy in Advanced Ovarian Cancer

¹ Department of Oncology and Palliative Medicine, Velindre Hospital, Whitchurch and ² Department of Pathology, Heath Park, Cardiff, School of Medicine, Cardiff University; and ³ Velindre NHS Trust, Whitchurch, Cardiff, United Kingdom

Requests for reprints: Zsuzsanna Tabi, Department of Clinical Oncology and Palliative Medicine, School of Medicine, Cardiff University, Velindre Hospital, Whitchurch, Cardiff CF14 2TL, United Kingdom. Phone: 44-29-20-196-137; Fax: 44-29-20-529-625; E-mail: Zsuzsanna.Tabi{at}velindre-tr.wales.nhs.uk.

Immunologic approaches are emerging as new treatment options in several types of cancer. However, whereas the ability of patients to develop potent CD8⁺ T-cell responses is crucial for efficient antitumor responses, immunocompetence and T-cell function are not tested routinely in patients entering immunotherapy. The objective of our study was to monitor T-cell function in advanced cancer and during chemotherapy. CD8⁺ T-cell function of 21 patients with advanced ovarian cancer (stages III-IV) was assessed by cytokine flow cytometry following stimulation of 42 PBMC samples with a panel of synthetic viral peptides in vitro, consisting of pan-Caucasian epitopes. CD8⁺ T-cell responses were significantly lower in patients with high levels (>200 units/mL) of Ca125 (marker of tumor load and progression) than in those with low Ca125 levels (P = 0.0013). In longitudinal studies of nine patients, chemotherapy was associated with decreasing Ca125 levels in seven cases and also with improvement or maintenance of CD8⁺ T-cell function in seven cases. After the full course of chemotherapy, five of nine patients in remission displayed potent CD8⁺ T-cell responses, whereas four of nine patients in progression displayed low or decreasing T-cell responses, pointing toward a correlation between T-cell function and clinical response. Our results show for the first time that CD8⁺ T-cell function is not permanently suppressed in advanced cancer and successful chemotherapy is associated with improved antigen-specific T-cell reactivity. We suggest that functional assays determining T-cell immunocompetence can be valuable tools for optimizing cancer immunotherapy for improved clinical success.

This article has been cited by other articles:

				A. Clayton, J. P. Mitchell, J. Court, S. Linnane, M. D. Mason, and Z. Tabi Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression J. Immunol., June 1, 2008; 180(11): 7249 - 7258. [Abstract] [Full Text] [PDF]

				N. Tsuda, D. Z. Chang, T. Mine, C. Efferson, A. Garcia-Sastre, X. Wang, S. Ferrone, and C. G. Ioannides Taxol Increases the Amount and T Cell Activating Ability of Self-Immune Stimulatory Multimolecular Complexes Found in Ovarian Cancer Cells Cancer Res., September 1, 2007; 67(17): 8378 - 8387. [Abstract] [Full Text] [PDF]